NCT06558604 - A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

March 31, 2032

Conditions

Lymphoma, Mantle-Cell

Interventions

DRUG

Obinutuzumab

1000 mg/40mL

DRUG

Glofitamab

10mg/mL

DRUG

Venetoclax Oral Product

10mg, 50mg and 100mg tablets

DRUG

Zanubrutinib Oral Capsule

80mg capsules

Trial Locations (17)

Unknown

RECRUITING

Az Sint-Jan Brugge - Oostende Av, Bruges

RECRUITING

Institut Jules Bordet, Brussels

RECRUITING

Chu de Liege, Liège

RECRUITING

Chu Ucl Namur - Site Godinne, Yvoir

RECRUITING

Aphp - Hopital Henri Mondor, Créteil

RECRUITING

Chu Dijon Bourgogne, Dijon

RECRUITING

Chu de Lille - Hopital Claude Huriez, Lille

RECRUITING

Institut Paoli Calmettes, Marseille

RECRUITING

Chu de Montpellier, Montpellier

RECRUITING

Chu de Nantes, Nantes

RECRUITING

Chu Lyon-Sud, Pierre-Bénite

RECRUITING

Chu de Reims - Hopital Robert Debre, Reims

RECRUITING

Chu Pontchaillou, Rennes

RECRUITING

Centre Henri Becquerel, Rouen

RECRUITING

Institut Curie - Site Saint-Cloud, Saint-Cloud

RECRUITING

Institut Curie, Saint-Cloud

RECRUITING

Institut de Cancerologie Strasbourg Europe, Strasbourg